Pharma firms reject Greece's new drug prices
This article was originally published in Scrip
Executive Summary
Many pharmaceutical firms are expected to make objections to some of the new drug prices that were announced by the Greek government's pricing committee last week. Novartis and GlaxoSmithKline, two of the top five players in country in sales terms, have told Scrip they have appealed against the prices for a significant number of their products.